StemCell Therapy

In 2017, for the first time, The Economist brought together Asian business leaders, political decision-makers and health-care entrepreneurs to discuss how to make longevity a source of healthy innovation. At the Longevity Summit 2018, The Economist will build on this momentum to foster thinking on the topic of living to 100.

The event will answer the following key questions:

About the 2018 summit:

The worlds over-60 population is already nearing a billionand its still growing. Low fertility rates and increasing life expectancy have the United Nations predicting that by 2050 there will be 2.1 billion of these older people, and around half of them will live in Asia.

Longevity is a polarising issue. Optimists enthuse about advances in biotechnology and the market power of a silver economy; doomsayers fear skyrocketing health-care costs and inadequate workforces. A more plausible, middle position is to see the challenges associated with an ageing population as inextricably linked with their solutions. Governments and businesses need healthy populations to sustain demand, productivity and growth. And as people age, they want to stay healthy, engaged and purposeful. Happily, these are complementary demands.

But across Asia, progress in meeting the challenges of ageing has been patchy. Japan and Singapore have made great strides in helping their populations cope with longevity. Hong Kong, Taiwan and Korea are catching up by embracing new ideas and policy solutions. Philippines, Vietnam and Malaysia enjoy demographic buoyancy, with younger populations for the moment, but in the coming decades they will face the same pressures as their greying neighbours. What lessons can Asias longevity leaders share when it comes to engaging the over-60 population in the economy and society? Can the longevity dividend offset the costs of increased demand for health care and social services?

Originally posted here:
The Longevity Summit 2018 | The Economist Events

This entry was posted on November 10, 2018 at 5:40 am and is filed under Longevity. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |